| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/26/2007 | US7235635 IRAK-4: compositions and methods of use |
| 06/26/2007 | US7235634 Comprises proteolytic enzymes for use as tools to identify modulators for treatment and prevention of gastrointestinal, cell proliferative and inflammatory diseases |
| 06/26/2007 | US7235625 Administering phosphodiestarase inhibitors and melanocortin receptor antagonist: synergistic mixture |
| 06/26/2007 | US7235588 Administering tyrphostin janus associated kinase inhibitor |
| 06/26/2007 | US7235565 Quinoline and quinolinones 4-substituted with a 3-(hetero)cyclylcarbonyl-1-imidazolinyl or 3-(hetero)cyclylcarbonyl-1-imidazolinonyl group; treating diabetes, glomerulonephritis, endotoxic shock, psoriasis, and arthritis |
| 06/26/2007 | US7235547 Pharmaceutical composition comprising an AChE inhibitor and a mGluR2 antagonist |
| 06/26/2007 | US7235535 Method of enhancing drainage of lacrimal system with purinergic receptor agonists |
| 06/26/2007 | US7235523 Methods for the treatment of hepatic disorders |
| 06/26/2007 | US7235403 Culturing a cell in the presence or absence of the compound, assaying the cell for expression or activity of gene(s), detecting the compound when expression of the genes is lower in the presence of the compound than in the absence |
| 06/26/2007 | US7235397 Methods and compositions for culturing spirochete and treating spirochetal diseases |
| 06/26/2007 | US7235392 Transforming B lymphocytes with Epstein-Barr virus, incubating transformed B lymphocytes with flavin N-oxide photosensitizer, adding non-toxic antioxidant, and exposing lymphocytes to activator such as photoradiation to activate photosensitizer |
| 06/26/2007 | US7235390 Mixture of Aspergillus derived protease, lipase, amylase and cellulase, and calcium, zinc, manganese, and magnesium cofactors; improved digestion |
| 06/26/2007 | US7235372 incubating a cell or tissue sample with a purified antibody or an antigen binding fragment that binds specifically to a portion of human NAIP protein, detecting binding of antibody to such cell or tissue sample |
| 06/26/2007 | US7235290 can be durably and firmly bonded to synthetic or living materials and used for medical and dental as well as technical applications |
| 06/26/2007 | US7235268 With a starch-free soluble fiber of Musa spp. fruit such as plantains or bananas |
| 06/26/2007 | US7235262 Use of bioactive fraction from cow urine distillate (‘Go-mutra’) as a bio-enhancer of anti-infective, anti-cancer agents and nutrients |
| 06/26/2007 | US7235259 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| 06/26/2007 | US7235248 Pharmaceutical compositions comprising cyclosporins |
| 06/26/2007 | US7235247 Aqueous solution; efficient penetration |
| 06/26/2007 | US7235237 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 06/26/2007 | CA2402791C Pre-formed sheet devices for topical application comprising a benefit agent coated solid gel sheet |
| 06/26/2007 | CA2379605C Topical suspension formulations containing ciprofloxacin and dexamethasone |
| 06/26/2007 | CA2339356C Prostate formula |
| 06/26/2007 | CA2307792C Method for regulating size and growth of vascularized normal tissue |
| 06/26/2007 | CA2235686C Indolin-2-one derivatives, process for their production and the pharmaceutical compositions containing them |
| 06/26/2007 | CA2185037C Iridaceae extract and compositions containing the same |
| 06/21/2007 | WO2007070632A2 Abuse resistant transmucosal drug delivery device |
| 06/21/2007 | WO2007070623A2 Transcatheter tumor immunoembolization |
| 06/21/2007 | WO2007069795A1 Method for prevention of tumor |
| 06/21/2007 | WO2007069709A1 Detecting agent and therapeutic agent for highly malignant breast cancer |
| 06/21/2007 | WO2007069671A1 Bicyclic heterocyclic compound |
| 06/21/2007 | WO2007069565A1 Bicyclic heterocyclic compound |
| 06/21/2007 | WO2007069423A1 Diagnostic marker for allergy |
| 06/21/2007 | WO2007069272A2 Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
| 06/21/2007 | WO2007068070A2 Composition containing an inhibitor of phosphodiesterase iii and a therapeutic alcohol for the treatment of atherosclerosis diseases |
| 06/21/2007 | WO2007039123A3 Combination therapy comprising an nk-3 antagonist and an antipsychotic agent |
| 06/21/2007 | WO2007038720A3 Modulation of tlr-mediated immune responses using adaptor oligonucleotides |
| 06/21/2007 | WO2007014238A3 Single dose use of cd20-specific binding molecules |
| 06/21/2007 | WO2007011880A3 Enhanced ocular neuroprotection/neurostimulation |
| 06/21/2007 | WO2007005763A3 Combination of a renin inhibitor and an insulin secretion enhancer or an insulin sensitizer |
| 06/21/2007 | WO2006131649A3 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones |
| 06/21/2007 | WO2006105401A3 Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist |
| 06/21/2007 | WO2006101782A3 A cysteine-containing peptide tag for site-specific conjugation of proteins |
| 06/21/2007 | WO2006099359A3 Methods of reducing microbial contamination |
| 06/21/2007 | WO2005046318A3 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| 06/21/2007 | US20070143871 Non-human transgenic animal models for hepatocellular carcinoma |
| 06/21/2007 | US20070142718 Noninvasive measurement of chemical substances |
| 06/21/2007 | US20070142470 Antidiabetic agents, antilipemic agents, dietetics, anticholesterol agents, hypotensive agents, cardiovascular disorders; (S)-Ethyl 2-methoxy-3-[4-{3-(4-methanesulfonyloxyphenyl) propylamino}phenyl]propionate |
| 06/21/2007 | US20070142459 Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections |
| 06/21/2007 | US20070142421 Pharmaceutical Composition |
| 06/21/2007 | US20070142388 Inhibitors of Akt activity |
| 06/21/2007 | US20070142354 Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| 06/21/2007 | US20070142351 Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands |
| 06/21/2007 | US20070142335 e.g. 2-amino-2-methyl-4-{1-methyl-5-[4-(3,4-dimethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol ; immunology-related disease selected from crohn's disease ulcerative colitis, multiple sclerosis, atopic dermatitis, insulin dependent diabetes mellitus, glomerular nephritis and rejection of a transplanted organ |
| 06/21/2007 | US20070142333 Cycloalkyl inhibitors of potassium channel function |
| 06/21/2007 | US20070142303 Buffer intracellular reduction and oxidation for the stressed cells in various disease states; beneficial as adjunctive support therapy, multiple chemical sensitivity syndrome, Charcot-Marie-Tooth disease, Dejerine-Sottas syndrome, Roussy-Levy syndrome, Rosenberg Chutorian syndrome, Korsakoff syndrome |
| 06/21/2007 | US20070142291 Methods for treating irritable bowel syndrome |
| 06/21/2007 | US20070142266 Combination comprising a P-gp inhibitor and an anti-epileptic drug |
| 06/21/2007 | US20070141669 Pregnancy-associated plasma protein-A2 (PAPP-A2) |
| 06/21/2007 | US20070141621 Method Of Screening For Sensitivity To Kinase Inhibitor Therapy |
| 06/21/2007 | US20070141185 Oral microemulsion composition comprising biphenydimethyldicarboxylate and silybin |
| 06/21/2007 | US20070141183 tetrahydroisohumulone and dihydro-isohumulone coadministration; antiinflammatory; for treatment of diabetes |
| 06/21/2007 | US20070141171 Novel composition and method for the treatment of hypertension |
| 06/21/2007 | US20070141169 Homeopathic drug composition and methods of use thereof |
| 06/21/2007 | US20070141154 Antidiabetic formulation and method |
| 06/21/2007 | US20070141137 Stable capsule preparation |
| 06/21/2007 | US20070141088 Glucan-based vaccines |
| 06/21/2007 | US20070141059 Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic |
| 06/21/2007 | US20070141058 Method of correcting immunopathological reactions and a medicament |
| 06/21/2007 | US20070141033 Purging of cells using viruses |
| 06/21/2007 | US20070140987 Promoting whole body health |
| 06/21/2007 | US20070140978 Adrenergic complement inhaler |
| 06/21/2007 | US20070140975 Opioid formulations having reduced potential for abuse |
| 06/21/2007 | CA2633603A1 Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit |
| 06/21/2007 | CA2629046A1 Abuse resistant transmucosal drug delivery device |
| 06/21/2007 | CA2626016A1 Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
| 06/20/2007 | EP1798242A2 New anti-GF-IR antibodies and their applications |
| 06/20/2007 | EP1797899A1 Preventive and remedy for collagen or elastin metabolic disorder |
| 06/20/2007 | EP1797898A1 Preventive/therapeutic drug for arteriosclerosis |
| 06/20/2007 | EP1797897A1 Medicinal composition containing meltrin antagonist |
| 06/20/2007 | EP1797892A1 Use of modified cyclosporins for the treatment of HCV disorders |
| 06/20/2007 | EP1797884A2 Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system |
| 06/20/2007 | EP1797883A2 Pharmaceutical composition comprising a cathepsin S inhibitor and an opioid |
| 06/20/2007 | EP1797882A1 Preventive and/or therapeutic medicine for rheumatoid arthritis |
| 06/20/2007 | EP1797877A1 Joint use of sulfonamide based compound with angiogenesis inhibitor |
| 06/20/2007 | EP1797869A2 Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 06/20/2007 | EP1797171A1 Methods for the generation of hepatocyte-like cells from human blastocyst-derived stem (hbs) |
| 06/20/2007 | EP1796728A2 Method and composition for preventing or treating diarrhea |
| 06/20/2007 | EP1796727A2 Method for the treatment of polycystic kidney disease |
| 06/20/2007 | EP1796726A2 Mixture of phytosterol ester(s) and 1,3-diglyceride(s) for use in the treatment of medical conditions |
| 06/20/2007 | EP1796725A1 Treatment or prevention of unscheluded bleeding in women on progestogen containing medication |
| 06/20/2007 | EP1796724A1 Stable multi-phased personal care composition |
| 06/20/2007 | EP1796691A1 Inorganic selenium for treatment of cancer |
| 06/20/2007 | EP1796660A2 Use of tellurium compounds for inhibition of interleukin-converting enzyme |
| 06/20/2007 | EP1796656A2 Composition for inhibiting or preventing the formation of a biofilm |
| 06/20/2007 | EP1534256A4 Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier |
| 06/20/2007 | EP1517687B1 Medicament for the treatment of the systemic inflammatory response syndrome |
| 06/20/2007 | EP1487824B1 Diamino-pyrimidines and their use as angiogenesis inhibitors |
| 06/20/2007 | EP1455770B1 Use of norepinephrine reuptake inhibitors for the treatment of tic disorders |
| 06/20/2007 | EP1381590B1 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |